肝纤维化无创诊断的研究进展

曹玉宁; 李森林

肝纤维化无创诊断的研究进展

聊城市人民医院消化内科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 3518
- HTML全文浏览量: 31
- PDF下载量: 1047
- 被引次数: 0
出版历程
- 出版日期: 2011-02-20

Research in the progress of non-invasive diagnosis of liver fibrosis

摘要

摘要: 肝纤维化是一种由不同肝病发展而来的威胁生命的疾病,是最常见的死因之一,以细胞外基质增加,组织重列并改建为特点。判断肝纤维化程度及炎症活动度的最可靠指标为肝脏活检,但活检是一项有创检查,应用有一定的限制,因而寻找准确、可靠地无创检查方法为肝纤维化的病情判断和疗效考核提供依据是非常有必要的。近年来,随着血清学和影像学的发展,血清标志物模型、瞬态弹性成像等可以比较准确的诊断肝纤维化,减少了对肝活检的需要,但是由于其各自的缺点至今没有一种无创方法可以替代肝活检的金标准地位,寻找一种理想的标志物仍需继续努力。
- 肝硬化
Abstract: Liver fibrosis is a life-threatening disease evolving from different liver disease,is one of the most common cause of death.Fibrosis is characterized by excessive deposition of extracellular matrix in the tissue and tissue restatement as consequence of chronic liver damage.Liver biopsy is the most reliable indicator of the degree of hepatic fibrosis and inflammatory activity,but biopsy is an invasive examination.There are some risks and limitations,so it is necessary to look for an accurate and reliable non-invasive method to provide the basis for diagnosis and treatment of liver fibrosis.In recent years,advances in serology and imageology such as serum marker panels,FibroScan,et al can assess fibrosis accurately and reduce the need for a liver biopsy.But at present,all have failed to completely replace liver biopsy because of their respective limitations in current researches.The searching for an ideal surrogate is still in progress.
- liver cirrhosis

HTML全文

参考文献(31)

[1]Manning DS,Afdhal NH.Diagnosis and quantitation offibrosis[J].Gastroenterology,2008,134(6):1670-1681.

[2]Bedossa P,Dargere D,Paradis V.Sampling variability ofliver fibrosis in chronic hepatitis C[J].Hepatology,2003,38(6):1449-1457.

[3]Gressner OA,Weiskirchen R,Gressner AM.Biomarkersof hepatic fibrosis,fibrogenesis and genetic pre-disposition pending between fiction and reality[J].J CellMol Med,2007,11(5):1031-1051.

[4]Dufour DR.Assessment of liver fibrosis:can serumbecome the sample of choice?[J].Clin Chem,2005,51(10):1763-1764.

[5]Tarcin O,Gedik N,Karakoyun B,et al.Serum prolidaseand IGF-1 as non-invasive markers of hepatic fibrosisduring four different periods after bile-ductligation inrats[J].Dig Dis Sci,2008,53(7):1938-1945.

[6]Kurien BT,Patel NC,Porter AC,et al.Prolidase deficiencyand the biochemical assays used in its diagnosis[J].AnalBiochem,2006,349(2):165-175.

[7]Kayadibi H,Gultepe M,Yasar B,et al.Diagnostic valueof serum prolidase enzyme activity to predict the liverhistological lesions in non-alcoholic fatty liver disease:Asurrogate marker to distinguish steatohepatitis fromsimple steatosis[J].Dig Dis Sci,2009,54(8):1764-1771.

[8]Friedman SL.Molecular regulation of hepatic fibrosis,an integrated cellular response to tissue injury[J].J BiolChem,2000,275(4):2247-2250.

[9]Zeremski M,Dimova R,Brown Q,et al.Peripheral CXCR3-associated chemokines as biomarkers of fibrosis inchronic hepatitis C virus Infection[J].J Infect Dis,2009,200(11):1774-1780.

[10]Zeremski M,Petrovic LM,Chiriboga L,et al.Intrahepaticlevels of CXCR3-associated chemokines correlate withliver inflammation and fibrosis in chronic hepatitis C[J].Hepatology,2008,48(5):1440-1414.

[11]Shaheen AA,Myers RP.Diagnostic accuracy of theaspartate aminotransferase-to-platelet ratio index for theprediction of hepatitis C-related fibrosis:a systematicreview[J].Hepatol,2007,46:912-921.

[12]Poynard T,McHutchison J,Manns M,et al.Biochemicalsurrogate markers of liver fibrosis and activity in arandomized trial of peginterferon alfa-2b and ribavirin[J].Hepatology,2003,38(2):481-492.

[13]Poynard T,Munteanu M,Imbert-Bismut F,et al.Prospe-ctive analysis of discordant results between biochemicalmarkers and biopsy in patients with chronic hepatitis C[J].Clinical Chemistry,2004,50(8):1344-1355.

[14]Romero Gómez M,Ramírez Martín del Campo M,OteroMA,et al.Comparative study of two models that usebiochemical parameters for the noninvasive diagnosisof fibrosis in patients with hepatitis C[J].Med Clin,2005,124(20):761-764.

[15]Marín-Gabriel JC,Solís-Herruzo JA.Noninvasiveassessment of liver fibrosis.Serum markers andtransient elastography(FibroScan)[J].Rev Esp EnfermDig,2009,101(11):787-799.

[16]Poon TC,Hui AY,Chan HL,et al.Prediction of liverfibrosis and cirrhosis in chronic hepatitis B infection byserum proteomic FIngerprinting:a pilot study[J].ClinChem,2005,51(2):328-335.

[17]Morra R,Munteanu M,Bedossa P,et al.Diagnostic value ofserum protein profiling by SELDI-TOF ProteinChip comparedwith a biochemical marker,FibroTest,for the diagnosis ofadvanced fibrosis in patients with chronic hepatitis C[J].Aliment Pharmacol Ther,2007,26(6):847-858.

[18]Callewaert N,Vlierberghe HV,Hecke AV,et al.Noninvasive diagnosis of liver cirrhosis using DNAsequencer-based total serum protein glycomics[J].NatMed,2004,10(4):429-434.

[19]Chen CY,Schmilovitz-Weiss H,Liu XE,et al.Serumprotein N-Glycans Profiling for the discovery of potentialbiomarkers for nonalcoholic steatohepatitis[J].JProteome Res,2009,8(2):463-470.

[20]Lim AK,Taylor-Robinson SD,Patel N,et al.Hepatic veintransit times using a microbubble agent can predictdisease severity non-invasively in patients with hepatitisC[J].Gut,2005,54(1):128-133.

[21]Janssens F,de Suray N,Piessevaux H,et al.Cantran-sient elastography replace liver histology fordetermination of advanced fibrosis in alcoholic patients:A real-life study[J].Clin Gastroenterol,2010[Epubahead of print].

[22]Castera L.Transient elastography and other noninvasivetests to assess hepatic fibrosis in patients with viralhepatitis[J].J Viral Hepat,2009,16(5):300-314.

[23]Bonnard P,SombiéR,Lescure FX,et al.Comparison ofelastography,serum marker scores,and histology for theassessment of liver fibrosis in hepatitis B virus(HBV)-infected patients in Burkina Faso[J].Trop Med Hyg,2010,82(3):454-458.

[24]Huwart L,Sempoux C,Vicaut E,et al.Magnetic resonan-ce elastography for the noninvasive staging of liverfibrosis[J].Gastroenterology,2008,135(1):32-40.

[25]RouvièreO,Yin M,Dresner MA,et al.MR elastographyof the liver:preliminary results[J].Radiology,2006,240(2):440-448.

[26]Yin M,Talwalkar JA,Glaser KJ,et al.Assessment ofhepatic fibrosis with magnetic resonance elastography[J].Clin Gastroenterol Hepatol,2007,5(10):1207-1213.

[27]Faria SC,Ganesan K,Mwangi DI,et al.MR Imagingof Liver Fibrosis:Current State of the Art[J].RadioGraphics,2009,29(6):1615-1635.

[28]Lewin M,Poujol-Robert A,Boelle PY,et al.Diffusion-weighted magnetic resonance imaging for theassessment of fibrosis in chronic hepatitis C[J].Hepatology,2007,46(3):658-665.

[29]Taouli B,Koh DM.Diffusion-weighted MR Imaging of theLiver[J].Radiology,2010,254(1):47-66.

[30]Taouli B,Tolia AJ,Losada M,et al.Diffusion-weighted MRIfor quantifcation of liver fbrosis:preliminary experience[J].AJR Am J Roentgenol,2007,189(4):799-806.

[31]Boulanger Y,Amara M,Lepanto L,et al.Diffusion-weighted MR imaging of the liver of hepatitis Cpatients[J].NMR Biomed,2003,16(3):132-136.

施引文献

资源附件(0)

访问统计